https://doi.org/10.4081/monaldi.2024.2685
Evaluation of the effectiveness of Tadalafil on improving pulmonary function and asthma severity in severe asthmatic patients: a randomized controlled trial study
Submitted: June 27, 2023
Accepted: November 21, 2023
Published: January 11, 2024
Accepted: November 21, 2023
Abstract Views: 628
PDF_EARLY VIEW: 180
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Phosphodiesterase inhibitors elevate the levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate, which have been associated with various anti-inflammatory effects that can help alleviate asthma symptoms. This study aims to assess the impact of Tadalafil, a selective phosphodiesterase inhibitor, on pulmonary function in patients with asthma. This study was a randomized, double-blind clinical trial conducted in 2021 at Imam Khomeini Hospital in Ahvaz, Iran. The study enrolled 44 patients with severe asthma, who were divided equally into a Tadalafil group and a placebo group. The Tadalafil group received 20 mg/day of Tadalafil, while the placebo group received a placebo at the same dose. The patients' spirometry tests, asthma quality of life questionnaire, 6-minute walk distance, and quality of life were measured at the beginning of the study and one month later. The study results indicated that there was no statistically significant difference between the Tadalafil group and the placebo group in terms of pulmonary parameters (p>0.05). Furthermore, the scores for patients' quality of life (p=0.167) and the 6-minute walk test (p=0.148) at the end of the study did not show any statistically significant improvement compared to the placebo group. Results showed that the use of Tadalafil (20 mg) once daily for one month in patients with severe asthma did not affect clinical and laboratory outcomes.
Boonpiyathad T, Sözener ZC, Satitsuksanoa P, Akdis CA. Immunologic mechanisms in asthma. Semin Immunol 2019;46:101333.
DOI: https://doi.org/10.1016/j.smim.2019.101333
Hammad H, Lambrecht BN. The basic immunology of asthma. Cell 2021;184:1469-85.
DOI: https://doi.org/10.1016/j.cell.2021.02.016
Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol 2020;42:5-15.
DOI: https://doi.org/10.1007/s00281-020-00785-1
Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014;35:195-233.
DOI: https://doi.org/10.1210/er.2013-1053
Laxmi V, Gupta R, Bhattacharya SK, et al. Inhibitory effects of sildenafil and tadalafil on inflammation, oxidative stress and nitrosative stress in animal model of bronchial asthma. Pharmacol Rep 2019;71:517-21.
DOI: https://doi.org/10.1016/j.pharep.2019.02.008
Zuo H, Cattani-Cavalieri I, Musheshe N, et al. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther 2019;197:225-42.
DOI: https://doi.org/10.1016/j.pharmthera.2019.02.002
Matera MG, Ora J, Cavalli F, et al. New avenues for phosphodiesterase inhibitors in asthma. J Exp Pharmacol 2021;13:291-302.
DOI: https://doi.org/10.2147/JEP.S242961
Maurice DH, Ke H, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014;13:290-314.
DOI: https://doi.org/10.1038/nrd4228
Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2014;165:152-64.
Wójcik-Pszczoła K, Jankowska A, Ślusarczyk M, et al. Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2, 6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. Bioorg Chem 2021;117:105409.
DOI: https://doi.org/10.1016/j.bioorg.2021.105409
Beute J, Manganiello V, KleinJan A. Phosphodiesterase 3 and 4 inhibition: facing a bright future in asthma control. In: Huang KHG, Tsai CHS, eds. Asthma diagnosis and management - approach based on phenotype and endotype. London: IntechOpen; 2018.
DOI: https://doi.org/10.5772/intechopen.74309
Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med 2022;205:17-35.
DOI: https://doi.org/10.1164/rccm.202109-2205PP
Borsi H, Raji H, Shoushtari MH, et al. Investigating the effect of sildenafil on improving lung function and quality of life in the patients with severe asthma. J Family Med Prim Care 2019;8:2361-3.
DOI: https://doi.org/10.4103/jfmpc.jfmpc_334_19
Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60:2101499.
DOI: https://doi.org/10.1183/13993003.01499-2021
Apfelbacher CJ, Jones CJ, Frew A, Smith H. Validity of three asthma-specific quality of life questionnaires: the patients' perspective. BMJ Open 2016;6:e011793.
DOI: https://doi.org/10.1136/bmjopen-2016-011793
Puthiyaveettil S, Edakalavan J. Role of tadalafil in patients with hypoxia/lung disease induced (group 3) pulmonary hypertension. Eur Respiratory Soc 2016;48:PA1877.
DOI: https://doi.org/10.1183/13993003.congress-2016.PA1877
Kim HS, Park JH, Park SJ, et al. Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. Korean J Intern Med 2007;22:37-9.
DOI: https://doi.org/10.3904/kjim.2007.22.1.37
Goudie AR, Lipworth BJ, Hopkinson PJ, et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014;2:293-300.
DOI: https://doi.org/10.1016/S2213-2600(14)70013-X
Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2014;165:152-64.
DOI: https://doi.org/10.1159/000368800
Vijayalaxmi, Gupta R, Gulati K, Ray A. Anti-allergic effect of sildenafil and tadalafil in ovalbumin induced bronchial asthma in rats. Int J Plant Anim Environ Sci 2021;11:342-51.
DOI: https://doi.org/10.26502/ijpaes.202109
Clayton RA, Dick CA, Mackenzie A, et al. The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. Respir Res 2004;5:4.
DOI: https://doi.org/10.1186/1465-9921-5-4
Ethics Approval
This study was approved by the Medical Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (Ethics code IR.AJUMS.REC.1398.920).How to Cite
Borsi, Seyed Hamid, Seyed Ali Asghar Fakhr Mousavi Fakhr Mousavi, Mehrdad Dargahi Mal-Amir, Heshmatollah Tavakol, and Hanieh Raji. 2024. “Evaluation of the Effectiveness of Tadalafil on Improving Pulmonary Function and Asthma Severity in Severe Asthmatic Patients: A Randomized Controlled Trial Study”. Monaldi Archives for Chest Disease, January. https://doi.org/10.4081/monaldi.2024.2685.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- M. Lusuardi, F. Blasi, C. Terzano, C. Cricelli, N. Crispino, L. Comarella, F. De Benedetto, C.M. Sanguinetti, L. Allegra, C.F. Donner, Standards of care and clinical predictors in patients hospitalised for a COPD exacerbation - The Italian SOS (Stratification Observational Study) , Monaldi Archives for Chest Disease: Vol. 71 No. 4 (2009): Pulmonary series
- K. Ahmad Dar, M. Shahid, A. Mubeen, R. Bhargava, Z. Ahmad, I. Ahmad, N. Islam, The role of noninvasive methods in assessing airway inflammation and structural changes in asthma and COPD , Monaldi Archives for Chest Disease: Vol. 77 No. 1 (2012): Pulmonary series
- A.L. Kruis, N.H. Chavannes, Potential benefits of integrated COPD management in primary care , Monaldi Archives for Chest Disease: Vol. 73 No. 3 (2010): Pulmonary series
- Manav Raj Singh Gill, Sparsh Gupta, Amit Sharma, Pranav Ish, Deepak Pandey, Evaluation of asthma control after reinforcement of proper inhaler techniques in a tertiary care center in northern India , Monaldi Archives for Chest Disease: Early Access
- M.L. Bartoli, E. Bacci, S. Cianchetti, F.L. Dente, A. Di Franco, B. Vagaggini, M. De Santis, E. Masino, P.L. Paggiaro, Some factors influencing quality of spontaneous or induced sputum for inflammatory cell analysis , Monaldi Archives for Chest Disease: Vol. 67 No. 2 (2007): Pulmonary series
- N. Ambrosino, M. Di Giorgio, A. Di Paco, The patients with severe Chronic Obstructive Pulmonary Disease and chronic respiratory insufficiency , Monaldi Archives for Chest Disease: Vol. 67 No. 3 (2007): Pulmonary series
- Roberto F.E. Pedretti, Francesco Fattirolli, Raffaele Griffo, Marco Ambrosetti, Elisabetta Angelino, Silvia Brazzo, Ugo Corrà , Nicolò Dasseni, Pompilio Faggiano, Giuseppe Favretto, Oreste Febo, Marina Ferrari, Francesco Giallauria, Cesare Greco, Manuela Iannucci, Maria Teresa La Rovere, Mario Mallardo, Antonio Mazza, Massimo Piepoli, Carmine Riccio, Simonetta Scalvini, Luigi Tavazzi, Pier Luigi Temporelli, Gian Francesco Mureddu, Cardiac Prevention and Rehabilitation “3.0â€: From acute to chronic phase. Position Paper of the ltalian Association for Cardiovascular Prevention and Rehabilitation (GICR-IACPR) , Monaldi Archives for Chest Disease: Vol. 88 No. 3 (2018)
- E. Migliore, P. Piccioni, G. Garrone, G. Ciccone, A. Borraccino, M. Bugiani, Changing prevalence of asthma in Turin school children between 1994 and 1999 , Monaldi Archives for Chest Disease: Vol. 63 No. 2 (2005): Pulmonary series
- R. Agarwal, A. Khan, A.N. Aggarwal, D. Gupta, Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis , Monaldi Archives for Chest Disease: Vol. 71 No. 4 (2009): Pulmonary series
- F. Salajka, V. BartoÅ¡, J. Novosad, J. Å t'ásek, J. Bis, M. Brtko, P. Polanský, V. KoblÞek, V. Sedlák, Failure of noninvasive prediction of pulmonary hypertension in patients with idiopathic pulmonary fibrosis , Monaldi Archives for Chest Disease: Vol. 75 No. 3 (2011): Pulmonary series
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
